Axogen

Axogen, founded in 2002, is a prominent biotechnology and medical technology firm specializing in peripheral nerve repair and regeneration. The company develops innovative surgical solutions designed to address complex nerve injuries and restore essential nerve function. By focusing on regenerative medicine, Axogen provides advanced tissue-based products that improve patient outcomes across various surgical procedures. Their commitment to biomedical science and next-generation surgical technology positions them as a leader in the medical devices and equipment manufacturing sector.

Operating with a workforce of 500-1,000 employees, Axogen maintains a robust organizational structure to support its research, development, and commercialization efforts. The company manages its operations across 5 locations, ensuring efficient distribution and support for its proprietary medical technologies. Meet Axogen's team to learn more about the leadership and professional expertise driving their mission to advance nerve repair solutions. Their operational footprint is designed to scale alongside the growing demand for specialized regenerative medical products in the global healthcare market.

Publicly traded on the NASDAQ under the ticker AXGN, Axogen demonstrates significant market presence within the medical technology industry. The company reported annual revenue of $251.2M, reflecting its strong commercial performance and the widespread adoption of its surgical graft and nerve repair systems. Explore financial highlights to review detailed metrics regarding their fiscal performance and growth trajectory. As a key player in the regenerative medicine space, Axogen continues to leverage its proprietary technology to compete effectively against other medical device manufacturers while maintaining a focus on long-term innovation and patient care.